Cargando…

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

BACKGROUND: Minimizing the risk of disease progression and exacerbations is the key goal of COPD management, as these are well-established indicators of poor COPD prognosis. We developed a novel composite end point assessing three important aspects (lung function, health status, and exacerbations) o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Dave, Maleki-Yazdi, M Reza, Tombs, Lee, Iqbal, Ahmar, Fahy, William A, Naya, Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928660/ https://www.ncbi.nlm.nih.gov/pubmed/27445468 http://dx.doi.org/10.2147/COPD.S101612

Ejemplares similares

Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials
por: Maleki-Yazdi, M. Reza, et al.
Publicado: (2016)

Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials
por: Ray, Riju, et al.
Publicado: (2018)

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
por: Maltais, François, et al.
Publicado: (2019)

Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study
por: Riley, John H., et al.
Publicado: (2018)

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: An Integrated Post Hoc Analysis
por: Naya, Ian P., et al.
Publicado: (2018)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
por: Cazzola, Mario, et al.
Publicado: (2013)

Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial
por: Kerwin, Edward M, et al.
Publicado: (2020)

Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study
por: Mehta, Rashmi, et al.
Publicado: (2014)

Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial
por: Bjermer, Leif H., et al.
Publicado: (2021)

Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol
por: Albertson, Timothy E, et al.
Publicado: (2015)

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
por: Albertson, Timothy E, et al.
Publicado: (2019)

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
por: Shukla, Soham, et al.
Publicado: (2021)

Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2020)

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2021)

Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
por: Lal, Chitra, et al.
Publicado: (2016)

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
por: Kerwin, Edward M, et al.
Publicado: (2017)

Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD – role of umeclidinium/vilanterol
por: Malerba, Mario, et al.
Publicado: (2014)

Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
por: Alcázar Navarrete, Bernardino, et al.
Publicado: (2018)

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
por: Miravitlles, Marc, et al.
Publicado: (2016)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
por: Molino, Antonio, et al.
Publicado: (2018)

The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study
por: Requena, Gema, et al.
Publicado: (2021)

Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study
por: Feldman, Gregory J., et al.
Publicado: (2017)

A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD
por: Siler, Thomas M, et al.
Publicado: (2016)

Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle
por: Shaikh, Nooreen, et al.
Publicado: (2017)

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD
por: Mehta, Rashmi, et al.
Publicado: (2018)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Long-term outcomes following first short-term clinically important deterioration in COPD
por: Naya, Ian P., et al.
Publicado: (2018)

Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model
por: Wilson, Michele R, et al.
Publicado: (2017)

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial
por: Kalberg, Chris, et al.
Publicado: (2016)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
por: Moretz, Chad, et al.
Publicado: (2020)

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
por: Brealey, Noushin, et al.
Publicado: (2015)

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
Publicado: (2016)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
por: Bremner, Peter R., et al.
Publicado: (2018)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial
por: Vogelmeier, Claus F., et al.
Publicado: (2021)

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models
por: Buikema, Ami R., et al.
Publicado: (2018)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
por: Bansal, Sandeep, et al.
Publicado: (2021)

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
por: Lipson, David A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1qn5v30fqppj5u9bevs5q1vocq